Trial Profile
A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 13 Mar 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 13 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.